People: HeartWare International Inc (HTWR.O)
HTWR.O on Nasdaq
92.43USD
19 Jun 2013
92.43USD
19 Jun 2013
Price Change (% chg)
$-1.86 (-1.97%)
$-1.86 (-1.97%)
Prev Close
$94.29
$94.29
Open
$94.43
$94.43
Day's High
$94.53
$94.53
Day's Low
$92.32
$92.32
Volume
157,677
157,677
Avg. Vol
222,792
222,792
52-wk High
$99.68
$99.68
52-wk Low
$74.77
$74.77
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
C. Raymond Larkin |
63 | 2010 | Non-Executive Independent Chairman of the Board |
Douglas Godshall |
48 | 2006 | President, Chief Executive Officer, Director |
Seth Harrison |
2004 | Non-Executive Deputy Chairman of the Board | |
Peter McAree |
48 | 2012 | Chief Financial Officer, Senior Vice President, Treasurer |
Jeffrey LaRose |
51 | 2009 | Executive Vice President, Chief Scientific Officer |
Lawrence Knopf |
51 | 2012 | Senior Vice President, General Counsel, Company Secretary |
James Schuermann |
44 | 2009 | Senior Vice President - Sales and Marketing |
Robert Yocher |
62 | 2011 | Senior Vice President - Regulatory & Quality Assurance |
David Hathaway |
65 | 2008 | Chief Medical Officer |
Cynthia Feldmann |
60 | 2012 | Independent Director |
Timothy Barberich |
64 | 2008 | Non-Executive Independent Director |
Robert Stockman |
58 | 2006 | Non-Executive Independent Director |
Robert Thomas |
67 | 2010 | Non-Executive Independent Director |
Denis Wade |
74 | 2004 | Non-Executive Independent Director |
Chris Taylor |
VP - Investor Relations & Corporate Communications |
Biographies
| Name | Description |
|---|---|
C. Raymond Larkin |
Mr. C. Raymond Larkin, Jr., is Non-Executive Independent Chairman of the Board of HeartWare International, Inc. He has been a director of HeartWare Limited and subsequently HeartWare International, Inc. since October 2008 and Chairman of the Board since June 2010. Mr. Larkin joined the board of directors of Align Technology, Inc. (Nasdaq:ALGN) in March 2004 and has served as Chairman since February 2006. Align Technology is engaged in the design, manufacture and marketing of novel orthodontic products. Mr. Larkin also serves on the board of Novasys Medical, Inc., a privately held company focused on the development of innovative therapies in women’s health. He is also a director of Neuropace, a privately held company developing implantable devices for treating neurological disorders, and TherOx, a company focused on treating oxygen-deprived tissue in heart-attack victims. Previously, from 1999 through May 2007, Mr. Larkin served on the Board of Davita, Inc., a New York Stock Exchange listed provider of dialysis services. Since July 2006, Mr. Larkin has served as a Venture Partner at Cutlass Capital, a healthcare venture capital firm, and, since January 2002 as an Executive Committee Member at Synecor, an incubator of innovative early stage medical technologies. Mr. Larkin spent approximately 15 years with critical care device company Nellcor Puritan Bennett, Inc, which he joined in 1983 as Vice President Sales and Marketing. He was appointed President and Chief Executive Officer of Nellcor in 1989. Larkin subsequently served as Chairman and Chief Executive Officer of Eunoe, Inc., a company focused on neurological disorders, until it was acquired by Integra LifeSciences Holdings Corporation in 2005. Mr. Larkin is a graduate of LaSalle University and a former Captain in the United States Marine Corps. |
Douglas Godshall |
Mr. Douglas Evan Godshall serves as President, Chief Executive Officer, Director of HeartWare International Inc. Mr. Godshall has been the Chief Executive Officer of HeartWare Limited and subsequently HeartWare International, Inc., since September 2006 and became a director of HeartWare Limited and subsequently HeartWare International, Inc., in October 2006. Prior to joining HeartWare Limited, Mr. Godshall served in various executive and managerial positions at Boston Scientific Corporation, where he had been employed since 1990, including as a member of Boston Scientific’s Operating Committee and since January 2005, as President, Vascular Surgery. Prior thereto, Mr. Godshall spent five years as Vice President, Business Development, at Boston Scientific, where he was focused on acquisition strategies for the cardiology, electrophysiology, neuroradiology and vascular surgery divisions. In March 2012, Mr. Godshall was appointed a director of pSpivida Corp., a public company traded on both the NASDAQ Stock Market and the ASX, that specializes in the development of miniaturized, injectable drug delivery systems. Mr. Godshall has a Bachelor of Arts in Business from Lafayette College and Masters of Business Administration from Northeastern University in Boston, Massachusetts. |
Seth Harrison |
Dr. Seth Loring Harrison, M.D., is Non-Executive Deputy Chairman of the Board of HeartWare International, Inc. He has been a director and deputy chairman of HeartWare Limited and subsequently HeartWare International, Inc., since November 2004 and was Chief Executive Officer of HeartWare, Inc. from July 2003 through November 2004. Since September 1999, Dr. Harrison has been Managing General Partner of Apple Tree Partners I, L.P., an early stage life sciences venture capital firm, which is a stockholder. Prior to September 1999, he held senior executive positions with Oak Investment Partners, Sevin Rosen Funds and Nazem & Company. Dr. Harrison received a Bachelor of Arts from Princeton University. He received his medical degree and a Masters of Business Administration from Columbia University and completed a surgery internship at Columbia Presbyterian Hospital in New York. Dr. Harrison serves on the board of and chairs the Finance Committee of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation-sponsored public-private partnership engaged in the development of anti-HIV microbicides. He also serves as Chairman on the boards of AIleron Therapeutics and Tokai Pharmaceuticals, privately held companies. |
Peter McAree |
Mr. Peter F. McAree serves as Chief Financial Officer, Senior Vice President, Treasurer of HeartWare International Inc. Mr. McAree most recently was Senior Vice President and Chief Financial Officer of Caliper Life Sciences, Inc., prior to the company's acquisition by PerkinElmer, Inc. in November, 2011. Mr. McAree has more than 25 years of financial management and public accounting experience. Mr. McAree served as Chief Financial Officer of Zymark prior to the company's merger with Caliper in 2003. During his eight years with Caliper, Mr. McAree served as Vice President of Finance and Treasurer before being promoted to CFO in 2008. Having also served in financial leadership positions in other industries, Mr. McAree began his career with Arthur Andersen LLP, Boston, where he held various positions over nearly a decade, most recently as Senior Manager, Enterprise Group in 1995. McAree is a Certified Public Accountant in Massachusetts. |
Jeffrey LaRose |
Mr. Jeffrey A. LaRose serves as Executive Vice President, Chief Scientific Officer of HeartWare International Inc. Mr. LaRose is Chief Scientific Officer and has been with the Company since its inception. Prior to joining HeartWare, since April 1999, he was in the development of HeartWare’s technology through his employment with Kriton Medical, which the Company acquired in 2003. He is responsible for all aspects of the design and physiological controls for HeartWare’s left ventricular assist device, the HeartWare LVAD System. Mr. LaRose leads the development of miniaturization technology and has 20 years of experience in hydraulic technology development including roles with AEA Technology Engineering Software and Babcock and Wilcox. He holds a Master of Science in Mechanical Engineering from the University of Akron, Ohio. |
Lawrence Knopf |
Mr. Lawrence Knopf serves as a Senior Vice President, General Counsel, Company Secretary of HeartWare International Inc. Mr. Knopf served in a legal positions at Boston Scientific Corporation, a global medical device company. From 2007, Mr. Knopf was Senior Vice President and Deputy General Counsel, from 1994, Vice President and Assistant General Counsel and from 1993, Assistant General Counsel. Previously, Mr. Knopf was a corporate associate at the Boston law firms of Bingham McCutchen, LLP and Gaston & Snow. Mr. Knopf received a Juris Doctor from the University of Michigan School of Law and holds a Bachelor of Science, Accounting and Political Science, from The Wharton School of the University of Pennsylvania. He is admitted to the Bar in Massachusetts, New York and Connecticut and is admitted as a Certified Public Accountant in Connecticut. |
James Schuermann |
Mr. James Schuermann serves as Senior Vice President - Sales and Marketing of HeartWare International Inc. Mr. Schuermann joined HeartWare in September 2007. He has responsibility for HeartWare’s sales and marketing activities across all markets. Mr. Schuermann has 15 years of sales and marketing experience in the medical device arena. Prior to joining HeartWare, he spent 9 years in sales and marketing at Boston Scientific Corporation. He progressed from sales through product management until being appointed Director of Marketing in 2005. Before joining Boston Scientific, he spent 5 years in medical sales and sales management at Sherwood Davis & Geck. Mr. Schuermann received his undergraduate degree in marketing from Kelley School of Business, Indiana University, Bloomington, and his MBA from Ageno School of Business, Golden Gate University, San Francisco. |
Robert Yocher |
Mr. Robert Yocher serves as Senior Vice President - Regulatory & Quality Assurance of HeartWare International Inc. Mr.Yocher has responsibility for the Company’s quality and regulatory activities. Between 1999 and 2011, Mr. Yocher was Vice President, Regulatory Affairs and Corporate Quality Compliance at Genzyme Corporation, a global biopharmaceuticals and medical device company. Previously, Mr. Yocher worked in a senior regulatory, quality and clinical positions at EDAP Technomed, Inc., a urological medical device company, BioField Corporation, a development stage medical device company, and Dornier Medical Systems, a therapeutic device company, among others. Mr. Yocher holds a Master of Health Science, Public Health Microbiology and Epidemiology, from Quinnipiac University and a Bachelor of Arts, Microbiology/Chemistry, from the University of Connecticut. |
David Hathaway |
Dr. David R. Hathaway serves as Chief Medical Officer of HeartWare International Inc. Prior to joining HeartWare, Dr. Hathaway served as a private consultant in the biotechnology and medical device industry from October 2006 to June 2008. From June 2003 to September 2006, Dr. Hathaway was the Chief Medical Officer of Arginox Pharmaceuticals. Prior to joining Arginox, Dr. Hathaway was Vice President, Clinical Development at Restoragen from May 2001 to February 2003. Dr. Hathaway was Vice President of Medical Affairs with Knoll Pharmaceutical Company until it was acquired by Abbott Laboratories. He oversaw the Medical Affairs Department and was responsible for clinical research, regulatory affairs, medical information and drug advocacy. He served as a Clinical Associate and Cardiology Fellow at the National Institutes of Health in Bethesda, Md. Dr. Hathaway has been section editor (Cardiovascular Diseases) of Kelley’s Textbook of Medicine and a member of the editorial boards of the Journal of Clinical Investigation, the Journal of the American College of Cardiology and Circulation. He is a member of the Association of American Physicians, the American College of Physicians and the American Society for Clinical Investigation and is a fellow in the American College of Cardiology. He earned his medical degree from the Indiana University School of Medicine. |
Cynthia Feldmann |
Ms. Cynthia L. Feldmann has been appointed as Independent Director of HeartWare International, Inc., effective March 1, 2012. Ms. Feldmann is a retired certified public accountant with 27 years of experience in two global accounting firms and currently serves on several public company and not-for-profit boards. She was the President and Founder of Jetty Lane Associates, a consulting firm, from 2005 until 2012. Previously, Ms. Feldmann served as the Life Sciences Business Development Officer for the Boston law firm of Palmer & Dodge, LLP from 2003 to 2005, and was a partner with KPMG LLP, primarily serving as Partner-in-Charge of its National Medical Technology Practice from 1994 to 2002. From 1975 to 1994, Ms. Feldmann was employed by Coopers & Lybrand (now PricewaterhouseCoopers LLP), and during that time was named Partner-in-Charge of its Life Sciences practice. Ms. Feldmann is a director of Steris Corporation, Hanger Orthopedic Group, Inc. and Atrius Health. She previously served on the Board of Hayes Lemmerz International, Inc. from 2006 until 2009. Ms. Feldmann has a Bachelor of Science, Accounting, from Boston College and holds a Professional Director Certification from the American College of Corporate Directors. |
Timothy Barberich |
Mr. Timothy Joseph Barberich is Non-Executive Independent Director of HeartWare International, Inc., since April 29, 2008. He is the founder and former President, Chief Executive Officer and Chairman of Sepracor Inc., a publicly traded pharmaceutical company based in Marlborough, Massachusetts which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He founded Sepracor in 1984 and was Chief Executive Officer from 1984 to May 2007 and Chairman of the Board from 1990 to 2007. From May 2007 to May 2008, Mr. Barberich served as Executive Chairman of Sepracor and served as Chairman of the Board from May 2008 through October 2009. Mr. Barberich has been the Chairman of BioNevia Pharmaceuticals since June 2008. He has also serves on the board of GI Dynamics, an Australian listed medical device company, since September 2011 and serves on the board of directors of the privately held companies, Tokai Pharmaceuticals and Euthymics Biosciences. Mr. Barberich has previously served on the board of BioSphere Medical, Inc., a NASDAQ listed biotechnology company, from December 1993 to 2010, and the privately held companies, Gemin X Biotechnologies from 2005 to 2011, and Resolvyx Pharmaceuticals from 2009 to 2010. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Bedford, Massachusetts-based Millipore Corporation, a company that provides separations products to the life science research, pharmaceutical, biotechnology and electronic markets. Mr. Barberich is a graduate of Kings College. He holds a Bachelor of Science degree in Chemistry. |
Robert Stockman |
Mr. Robert Bernard Stockman is Non-Executive Independent Director of HeartWare International, Inc., since December 11, 2006. Since 1999, Mr. Stockman has been the President and Chief Executive Officer of Group Outcome LLC, a U.S.-based merchant banking firm which deploys its capital and that of its financial partners in private equity and venture capital investments in medical technology companies. He is also the co-founder, Chairman and CEO of REVA Medical, Inc., an interventional coronary medical device company. Prior to establishing Group Outcome LLC, Mr. Stockman spent eighteen years with Johnston Associates and Narragansett Capital Corporation, where he focused on venture capital investments in healthcare. Mr. Stockman holds a Bachelor’s degree from Harvard College and a Master in Business Administration from The Tuck School at Dartmouth College. |
Robert Thomas |
Mr. Robert Bain Thomas is Non-Executive Independent Director of HeartWare International, Inc. He has been a director of HeartWare Limited and subsequently HeartWare International, Inc., since November 2004 and Chairman of the Board of HeartWare Limited and subsequently HeartWare International, Inc. for the period from February 2009 to June 2010. He is currently a director of the following Australian public companies: Virgin Australia Limited (formerly Virgin Blue Holdings Limited), Reva Medical, Inc. and TAL Limited (formerly Tower Australia Limited), the latter of which Mr. Thomas serves as Chairman. He also serves on the board of the privately held company, AUS Bio Limited. Between October 2004 and September 2008, Mr. Thomas was a consultant to Citigroup Corporate and Investment Bank and was Chairman of Global Corporate and Investment Bank, Australia and New Zealand of Citigroup Global Markets Australia Pty Limited between March 2003 and September 2004. Prior thereto, Mr. Thomas was CEO of Citigroup’s (formerly known as Salomon Smith Barney) Corporate and Investment Bank, Australia and New Zealand from October 1999 until February 2003. Mr. Thomas is a member of the Advisory Board of Inteq Limited and Nomura Australia and is a Fellow of the Australian Institute of Company Directors. Mr. Thomas is a director of O’Connell Street Associates and Grahger Capital Securities as well as being President of the State Library Council of New South Wales in Australia. Mr. Thomas holds a Bachelor of Economics from Monash University, Australia. He is currently Chairman of the Stockbrokers Association of Australia and is a Master Stockbroker and has also been a member of the Financial Services Institution of Australia (previously known as the Securities Institute of Australia) for almost four decades and a Fellow for a decade. |
Denis Wade |
Dr. Denis Newell Wade is Non-Executive Independent Director of HeartWare International, Inc., since December 15, 2004. From 1998 until his retirement in 2003, Dr. Wade was Managing Director of Johnson & Johnson Research Pty Ltd, a research arm of Johnson & Johnson. Prior to that position, he was the Foundation Professor of Clinical Pharmacology at the University of New South Wales in Australia. Dr. Wade has served on a number of industry and Government bodies in Australia. He is a former President of the Australian Society of Clinical and Experimental Pharmacology and has held senior positions in the International Union of Pharmacology, serving as Chairman of the Clinical Pharmacology Section. Dr. Wade holds a Bachelor degree in Medicine and Surgery from the University of New South Wales (Australia) and a Doctorate in Philosophy from Oxford (in the United Kingdom). He was awarded an Honorary Doctorate in Science from the University of New South Wales. He is a Fellow of the Royal Australasian College of Physicians and the Australian Academy of Technological Sciences and Engineering. Dr. Wade currently serves as a director of ChemGenex Pharmaceuticals Ltd., a company listed on the Australian Securities Exchange (“ASX”), and Biotron Limited, also listed on the ASX. |
Chris Taylor |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
C. Raymond Larkin |
-- |
Douglas Godshall |
2,555,690 |
Seth Harrison |
-- |
Peter McAree |
-- |
Jeffrey LaRose |
1,640,420 |
Lawrence Knopf |
2,419,240 |
James Schuermann |
810,890 |
Robert Yocher |
1,422,840 |
David Hathaway |
1,140,000 |
Cynthia Feldmann |
-- |
Timothy Barberich |
-- |
Robert Stockman |
-- |
Robert Thomas |
-- |
Denis Wade |
-- |
Chris Taylor |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
C. Raymond Larkin |
0 | 0 |
Douglas Godshall |
10,000 | 544,364 |
Seth Harrison |
0 | 0 |
Peter McAree |
0 | 0 |
Jeffrey LaRose |
1,400 | 114,262 |
Lawrence Knopf |
0 | 0 |
James Schuermann |
6,428 | 202,114 |
Robert Yocher |
0 | 0 |
David Hathaway |
0 | 0 |
Cynthia Feldmann |
0 | 0 |
Timothy Barberich |
0 | 0 |
Robert Stockman |
0 | 0 |
Robert Thomas |
0 | 0 |
Denis Wade |
0 | 0 |
Chris Taylor |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
THOMAS ROBERT BAIN |
1,370 | $91.25 |
THOMAS ROBERT BAIN |
1,286 | $89.57 |
THOMAS ROBERT BAIN |
57 | $94.05 |
THOMAS ROBERT BAIN |
14 | $94.18 |
THOMAS ROBERT BAIN |
700 | $92.83 |
THOMAS ROBERT BAIN |
286 | $91.07 |
THOMAS ROBERT BAIN |
200 | $93.13 |
HATHAWAY DAVID R |
5,934 | $95.05 |
HATHAWAY DAVID R |
4,491 | $19.22 |
THOMAS ROBERT BAIN |
2,300 | $94.85 |
HATHAWAY DAVID R |
2,400 | $19.55 |
HATHAWAY DAVID R |
2,400 | $95.15 |
THOMAS ROBERT BAIN |
200 | $97.69 |
HATHAWAY DAVID R |
1,900 | $97.31 |
HATHAWAY DAVID R |
12,842 | $95.46 |
HATHAWAY DAVID R |
17,140 | $19.51 |
HATHAWAY DAVID R |
2,398 | $96.16 |
HARRISON SETH LORING |
126,768 | $0.00 |
KNOPF LAWRENCE J |
2,000 | $97.72 |
LAROSE JEFFREY A |
7,471 | $97.68 |
THOMAS ROBERT BAIN |
715 | $97.34 |
HATHAWAY DAVID R |
10,000 | $19.40 |
HARRISON SETH LORING |
105,136 | $0.00 |
THOMAS ROBERT BAIN |
714 | $98.35 |
HARRISON SETH LORING |
250,000 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
